Immunotherapy For PD and AD: A Promising Disease Modifying Therapy
Preprint
- 26 July 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Alzheimer's Disease (AD) and Parkinson's Disease (PD) are two neurodegenerative diseases posing a significant disease burden due to their increasing prevalence and socio-economic cost. Traditional therapeutic approaches for these diseases exist but provide limited symptomatic relief without addressing the underlying pathologies. This review examines the potential of immunotherapy, specifically monoclonal antibodies (mAbs), as disease-modifying treatments for AD and PD. We analyze the pathological mechanisms of AD and PD, focusing on the roles of amyloid-beta (Aβ), tau (τ), and alpha-synuclein (α-syn) proteins. We discuss the latest advancements in mAbs therapies targeting these proteins, evaluating their efficacy in clinical trials and preclinical studies. We also explore the challenges faced in translating these therapies from bench to bedside, including issues related to safety, specificity, and clinical trial design. Additionally, we highlight future directions for research, emphasizing the need for combination therapies, improved biomarkers, and personalized treatment strategies. This review aims to provide insights into the current state and future potential of antibody-based immunotherapy in modifying the course of AD and PD, ultimately improving patient outcomes and quality of life.Keywords
All Related Versions
- Version 1, 2024-07-26, Preprints
- Published version: Cells, 13 (18), 1527.
This publication has 28 references indexed in Scilit:
- Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer DiseaseJAMA Neurology, 2022
- ENGAGE and EMERGE: Truth and consequences?Alzheimer's & Dementia, 2021
- Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054Movement Disorders, 2019
- Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluidAnnals of Neurology, 2019
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson DiseaseJAMA Neurology, 2018
- Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelaeNature Communications, 2017
- First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteersMovement Disorders, 2016
- First‐in‐human, double‐blind, placebo‐controlled, single‐dose escalation study of aducanumab (BIIB037) in mild‐to‐moderate Alzheimer's diseaseAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2016
- Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With GantenerumabArchives of Neurology, 2012
- Testing the amyloid hypothesis of Alzheimer's disease in vivoThe Lancet Neurology, 2010